Viking Therapeutics

About Viking Therapeutics

Viking Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

Products & Services

VK2735:A drug candidate for obesity and metabolic disorders.

VK2809:A drug candidate for NASH/MASH (non-alcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis).

VK0214:A drug candidate for X-ALD (X-linked adrenoleukodystrophy), under the rare disease program.

VK5211:An orally available small molecule drug candidate for hip fracture and muscle wasting.

EPOR Agonist Program:A program targeting anemia.

Specialties

Metabolic Disorders Endocrine Disorders Rare Diseases Obesity Treatment NASH/MASH Treatment Muscle Wasting Treatment Diabetes Treatment Anemia Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 632500000 MR: - FA: $632.5 million FAN: 632500000	D: 2024-03-04 FD: 2024-03-04	11 investors
2	RT: Public Offering T: - FT: Public Offering	A: 550000000 MR: - FA: approximately $550.0 million FAN: 550000000	D: 2024-02-28 FD: 2024-02-28	11 investors
3	RT: Public Offering T: - FT: Public Offering	A: 350000000 MR: - FA: $350.0 million FAN: 350000000	D: 2024-02-27 FD: 2024-02-27	6 investors
4	RT: Public Offering T: - FT: Public Offering	A: 287500000 MR: - FA: approximately $287.5 million FAN: 287500000	D: 2023-04-03 FD: 2023-04-03	9 investors
5	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: 250 million FAN: 250000000	D: 2023-03-29 FD: 2023-03-29	8 investors

Public Offering of Common Stock Latest

2024-03-04

$632.5M

11 investors (Pro only)

Public Offering 2024-02-28

$550.0M

Public Offering 2024-02-27

$350.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Lawson Macartney

Chairman

M

Matthew W. Foehr

Chief Executive Officer of OmniAb, Inc.

K

Kathy Rouan

Senior Vice President and Head of Projects, Clinical Platforms and Sciences at GlaxoSmithKline

C

Charles A. Rowland Jr.

Board Member and Strategic Advisor

M

Matthew Singleton

Executive Vice President and Chief Financial Officer

B

Brian Lian

President and Chief Executive Officer

View 7 more team members with Pro

Unlock Full Team Directory

Recent News